Skip to main content
. 2022 Jul 18;12(13):5710–5726. doi: 10.7150/thno.71832

Figure 8.

Figure 8

cTBS enhanced BDNF expression in the peri-infarct zone after PT stroke. (A) (a-d) Representative micrographs of DCX and BDNF double labeling in the peri-infarct area 6 days after PT stroke. The insert shows a zoomed view of DCX-positive neuroblast with high level of BDNF localization in cell soma, and the visible BDNF puncta with bright fluorescence spots around infarct border in cTBS-treated group. (B) (a, b) Representative Western blots and quantitative analyses of BDNF expression in peri-infarct proteins 6 days after PT stroke. (C) (a,b) Representative co-staining of BDNF (red), and p-TrkB (green) in the peri-infarct area 6 days after PT stroke. (c) Reprehensive fluorescence intensity profiles and the different degree of co-localization calculated on BDNF/p-TrkB co-immunostained images. Note the fluorescence peaks in cTBS group are higher and more closely associated compared to those in PT groups. Magnification: ×40, scale bar: 10 μm. Data are mean ± SE from 4-7 animals in each group. *P < 0.05 versus Ctl, #P < 0.05 versus PT group without cTBS treatment.